Comparative Stroke, Bleeding, and Mortality

ARTICLE IN PRESS Table Demographic and Clinical Characteristics of Medicare Beneficiaries Initiating Warfarin, Dabigatran, Rivaroxaban, or Apixaban for Nonvalvular Atrial Fibrillation from 2010 to 2015, Prior to Inverse Probability of Treatment Weighting Characteristic, % Warfarin (n = 183,318) Dabigatran (n = 86,198) Rivaroxaban (n = 106,389) Apixaban (n = 73,039) Maximum Pairwise SM D * Age, years (mean) 75.8 75.5 74.9 75.2 0.15 Female 48.0 47.6 46.1 47.8 0.04 Race/ethnicity White 91.8 91.8 91.9 92.4 0.02 Black 3.8 3.5 3.5 3.7 0.02 Other 4.4 4.7 4.6 3.9 0.04 Medical comorbidities Diabetes 34.2 33.4 32.0 33.9 0.05 Hypercholesterolemia 37.7 39.5 38.1 38.1 0.04 Hypertension 86.3 86.3 85.9 87.6 0.05 Kidney failure Acute 4.9 3.3 3.6 5.5 0.11 Chronic 12.1 9.6 8.5 13.5 0.16 Obesity 15.1 13.5 16.6 18.7 0.14 Peptic ulcer disease 0.4 0.4 0.4 0.4 0.01 Prior hospitalized bleeding 0.6 0.5 0.4 0.5 0.03 Smoking 20.5 17.9 22.3 24.4 0.16 Cardiovascular disease Acute myocardial infarction Past 1-30 days 1.5 1.0 1.3 1.4 0.04 Past 31-183 days 0.8 0.7 0.7 1.0 0.03 Coronary revascularization 15.6 14.4 14.5 16.4 0.05 Heart failure Hospitalized 3.6 3.1 2.9 3.5 0.04 Outpatient 12.6 12.8 10.7 11.8 0.06 Other ischemic heart disease 44.6 43.9 42.1 45.1 0.05 Stroke Past 1-30 days 2.2 1.9 1.9 2.1 0.02 Past 31-183 days 1.2 1.3 1.1 1.5 0.03 Other Transient ischemic attack 6.3 6.4 6.0 6.6 0.03 Cardioablation 1.8 2.2 2.1 2.4 0.04 Cardioversion 6.9 9.2 9.1 10.5 0.13 Other medical conditions Falls 5.0 4.5 4.6 4.7 0.02 Fractures 1.4 1.3 1.3 1.3 0.02 Syncope 8.7 8.5 8.8 9.7 0.04 Walker use 2.7 2.4 2.2 2.5 0.04 CHA 2 DS 2 -VASc scor e y 0-1 2.9 3.3 3.4 2.6 0.04 2 14.6 16.0 17.5 15.6 0.08 3 27.9 28.4 29.9 28.9 0.05 4 28.8 28.4 27.2 27.9 0.04 5 16.0 14.9 14.0 15.4 0.05 ≥ 6 9.9 9.1 8.0 9.6 0.07 HAS-BLED score z 1 9.3 9.2 9.6 8.3 0.05 2 44.9 46.1 46.7 43.9 0.06 3 31.0 31.4 31.3 32.2 0.02 ≥ 4 14.8 13.3 12.4 15.6 0.09 Medication use General Estrogen replacement 1.9 2.3 2.1 1.9 0.03 H2-antagonists 5.3 5.0 4.9 5.2 0.02 4 The American Journal of Medicine, Vol 000, No 000, && 2019